{
  "docId": "019de070-c58c-706c-98f1-9eec26811648",
  "docSlug": "2a1e5b2d3a1cb25fe50abb3e75ae9bdf",
  "documentTitle": "Alkermes | Investor Day Presentation Deck | 144 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 66,
  "pageCount": 132,
  "prevPage": 65,
  "nextPage": 67,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines the patient population (refractory to prior therapies) and the statistical design (Simon Two-Stage) used to determine cohort expansion.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-c58c-706c-98f1-9eec26811648/66",
  "deckHref": "/decks/019de070-c58c-706c-98f1-9eec26811648",
  "deckJsonHref": "/decks/019de070-c58c-706c-98f1-9eec26811648.json",
  "deckAnchorHref": "/decks/019de070-c58c-706c-98f1-9eec26811648#slide-66",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.44,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "ARTISTRY-1 Monotherapy Study Melanoma Cohort: Protocol-defined efficacy response criteria achieved, triggered Simon Two-Stage expansion cohort; Second stage of enrollment underway",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "185d33d6-b547-48ca-b44d-42c4ad096af3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.44,
        "x": 0.06,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Key Inclusion Criteria: Progressed on Immune checkpoint inhibitor (e.g., anti-PD-(L)1 with or without anti-CTLA-4) and Targeted agent as appropriate (e.g., BRAF inhibitor if BRAF-mut)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b30bcb9-9374-473d-8ef4-7c7fd40611bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "table",
      "text": "ARTISTRY-1 Simon Two Stage | Stage 1 N | Enroll more if | Stage 2 N | Total | Refractory melanoma expansion | 21 | >2 PR/CR | 20 | 41",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "349ff4b1-6e4e-4eef-9c89-a6209a530852",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ARTISTRY-1 Nemvaleukin Melanoma Monotherapy Cohort Focused on Unmet Need",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1e2a318-e3b7-4114-9214-79b54d39b7f3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "Simon Two-Stage Design",
      "slug": null,
      "matchId": "248964eb-e4d4-47b6-bdf9-a886d62036d3",
      "evidence": "The table explicitly labels the design as 'ARTISTRY-1 Simon Two Stage' and lists the decision criteria for expansion.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 69,
      "from": 55,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "59dd9c04-c6d4-46f5-9a3a-eaa6b3829180",
      "evidence": "Slides 55-69 detail the development and potential of Nemvaleukin alfa.",
      "position": 1,
      "objective": "To present Nemvaleukin alfa as a potential game-changer in cancer treatment",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.8,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}